Prevention of acute kidney injury using vasoactive or antiplatelet treatment: three strikes and out?
Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas2Associate Editor, JAMA.
Wolfgang C
WC
Winkelmayer
Division of Renal Diseases and Hypertension, Department of Medicine, University of Texas Medical School, Houston, Texas.
Kevin W
KW
Finkel
D058186:Acute Kidney Injury / Q000517:prevention & control*; D058647:Adrenergic alpha-2 Receptor Agonists / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects*; D006348:Cardiac Surgical Procedures; D003000:Clonidine / Q000008:administration & dosage*; D005260:Female; D018818:Fenoldopam / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D017582:Renal Replacement Therapy / Q000379:methods*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D058647:Adrenergic alpha-2 Receptor Agonists; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D018818:Fenoldopam; D003000:Clonidine; D001241:Aspirin